Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
magnesium + palmitoylethanolamide + high molecular weight hyaluronic acid + vitamin B6 + vitamin D + progesterone
- Development stage
- Unknown
- Lead developer
- Lo.Li. Pharma
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Oral, Vaginal
01
Overview
This combination therapy is an investigational regimen being studied by the University of Roma La Sapienza for the prevention of preterm birth in women with a short cervix. It consists of a daily oral supplement containing magnesium (450 mg), palmitoylethanolamide (200 mg), high-molecular-weight hyaluronic acid (200 mg), vitamin B6 (2.6 mg), and vitamin D (2000 IU), administered alongside the standard-of-care vaginal progesterone (200 mg). The treatment aims to reduce the incidence of preterm delivery by leveraging the synergistic effects of its components: progesterone maintains uterine quiescence; magnesium acts as a tocolytic; palmitoylethanolamide (PEA) provides anti-inflammatory effects via PPAR-alpha activation; high-molecular-weight hyaluronic acid (HMWHA) offers structural support and anti-inflammatory properties; and vitamins B6 and D support maternal-fetal immune and metabolic health.
- Other names
- magnesium + palmitoylethanolamide + high molecular weight hyaluronic acid + vitamin B6 + vitamin D + vaginal progesterone-University of Roma La Sapienza-preterm birthMagnesium-PEA-HMW Hyaluronic Acid-Vitamin B6-Vitamin D + Vaginal Progesterone
02
Targets
CaV (Voltage-gated calcium channel protein complex)PGRMC1VDR (Vitamin D receptor)PPARA (Peroxisome proliferator-activated receptor alpha)PR (Progesterone receptor)
Beyond the preview
Go deeper on magnesium + palmitoylethanolamide + high molecular weight hyaluronic acid + vitamin B6 + vitamin D + progesterone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on magnesium + palmitoylethanolamide + high molecular weight hyaluronic acid + vitamin B6 + vitamin D + progesterone.